Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Wierda

Showing results (101-110 of 181) with videos related to

Pageof 19
Sort By:
Oncotarget|March 22, 2021
STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cellsUri Rozovski, David M Harris, Ping Li, et al.
Leukemia & Lymphoma|February 28, 2022
Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitorsAkash Mukherjee, Denái R Milton, Elias J Jabbour, et al.
Haematologica|May 14, 2016
Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysisKoji Sasaki, Hagop Kantarjian, Elias Jabbour, et al.
Clinical Lymphoma & Myeloma|December 16, 2005
T-cell prolymphocytic leukemia: a single-institution experienceFarhad Ravandi, Susan O'Brien, Dan Jones, et al.
International Journal of Hematology|February 22, 2018
Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutationsKiran Naqvi, Jorge E Cortes, Raja Luthra, et al.
Molecular Cancer Research : MCR|March 4, 2015
Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL CellsUri Rozovski, Srdana Grgurevic, Carlos Bueso-Ramos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2005
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemiaWilliam Wierda, Susan O'Brien, Sijin Wen, et al.
Blood|October 22, 2009
Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemiaJohn C Byrd, Thomas J Kipps, Ian W Flinn, et al.
Leukemia Research|February 16, 2006
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndromeKaren W L Yee, Jorge Cortes, Alessandra Ferrajoli, et al.
Leukemia & Lymphoma|May 15, 2024
Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemiaJennifer Marvin-Peek, Wei-Ying Jen, Hagop M Kantarjian, et al.
Pageof 19

Showing results (101-110 of 181) with videos related to

Sort By:
Pageof 19
Oncotarget|March 22, 2021
STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cellsUri Rozovski, David M Harris, Ping Li, et al.
Leukemia & Lymphoma|February 28, 2022
Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitorsAkash Mukherjee, Denái R Milton, Elias J Jabbour, et al.
Haematologica|May 14, 2016
Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysisKoji Sasaki, Hagop Kantarjian, Elias Jabbour, et al.
Clinical Lymphoma & Myeloma|December 16, 2005
T-cell prolymphocytic leukemia: a single-institution experienceFarhad Ravandi, Susan O'Brien, Dan Jones, et al.
International Journal of Hematology|February 22, 2018
Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutationsKiran Naqvi, Jorge E Cortes, Raja Luthra, et al.
Molecular Cancer Research : MCR|March 4, 2015
Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL CellsUri Rozovski, Srdana Grgurevic, Carlos Bueso-Ramos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2005
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemiaWilliam Wierda, Susan O'Brien, Sijin Wen, et al.
Blood|October 22, 2009
Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemiaJohn C Byrd, Thomas J Kipps, Ian W Flinn, et al.
Leukemia Research|February 16, 2006
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndromeKaren W L Yee, Jorge Cortes, Alessandra Ferrajoli, et al.
Leukemia & Lymphoma|May 15, 2024
Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemiaJennifer Marvin-Peek, Wei-Ying Jen, Hagop M Kantarjian, et al.
Pageof 19